DalCor is developing precision treatments for cardiovascular disease by genetically targeting patients that will derive clinical benefits. The company’s first development program, dalcetrapib, is intended to reduce cardiovascular events in a genetically distinct subset of patients.
A pharmacogenomics analysis which was performed on 5,749 of the 17,000-patient dal-Outcomes study showed that patients with acute coronary syndrome (ACS) having an AA polymorphism at the rs1967309 location in the ADCY9 gene had significantly fewer cardiovascular events when treated with dalcetrapib, a CETP inhibitor, than with placebo. DalCor has secured a world-wide exclusive license from Roche for dalcetrapib together with rights to the ADCY9 genetic marker.
DalCor will sponsor the dal-GenE study, which is planned to include 5,000 patients to prospectively confirm the cardiovascular outcomes improvement seen in the genetic subpopulation of the dal-Outcomes study. The study will commence in the first half of 2016 and will be performed in over 30 countries.
In addition to the dal-GenE study, DalCor will sponsor additional research to investigate expanding the indications for which dalcetrapib could have clinical utility.
DalCor Pharmaceuticals has offices in Montreal, San Mateo, U.S.A., Zug, Switzerland and Stockport, U.K.
1010 Sherbrooke St. West, Suite 408
Montreal, Quebec H3A 2R7